2020 Year in Review: Amyloidosis

Contrasting with previous assessments of ventricular function, myocardial function index was easily derived from cardiac MRI integrating blood pool and myocardial volumes as factors contributing to myocardial function. Read More ›

This is the first study to demonstrate an association between complete remission and improved cardiac structure and function in patients with advanced light chain amyloidosis. Read More ›

While survival in patients with light chain cardiac amyloidosis is limited, achieving survival beyond 3 years is possible, particularly when treated promptly by an experienced multidisciplinary team. Read More ›

Correlations with survival and depth of organ response among kidney, heart, and liver are important, thereby suggesting a modification for organ response criteria to a graded response system from the current response/nonresponse system. Read More ›

Increased rates of deep hematologic responses with associated prolonged major organ deterioration progression-free survival support the benefit of daratumumab in patients newly diagnosed with light chain amyloidosis. Read More ›

The benefit of daratumumab-VCd was retained over VCd alone across cardiac stages for hematologic complete response, major organ deterioration progression-free survival, major organ deterioration event-free survival, and organ responses. Read More ›

Results from the phase 3 ANDROMEDA study suggest that the addition of daratumumab to standard of care was superior to standard of care alone, resulting in deeper and more rapid hematologic responses and improved clinical outcomes with an acceptable safety profile. Read More ›

In a study with a median follow-up of 22.9 months, subcutaneous daratumumab combined with cyclophosphamide + bortezomib + dexamethasone represents a promising new regimen for newly diagnosed patients with light chain amyloidosis. Read More ›

In cases of relapsed or refractory systemic light chain amyloidosis, continuous ixazomib plus dexamethasone may be an important treatment choice for this patient population with limited treatment options. Read More ›

Failing to recognize cardiomyopathy and linked comorbidities that serve as early indicators of light chain amyloidosis, frequently delays the treatment of these conditions by cardiologists and other clinicians. Read More ›

Page 2 of 2

Subscribe to Amyloidosis News

Stay up to date with Amyloidosis News & updates by subscribing to receive the free AMN e‑Newsletter.

I'd like to receive: